Olanzapine/samidorphan in schizophrenia and bipolar I disorder: a profile of its use in the USA
Declarations
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest E.S. Kim is a contracted employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. Z.T. Al-Salama, a salaried employee of Adis International Ltd/Springer Nature and an editor of Drugs & Therapy Perspectives, was not involved in any publishing decisions for the manuscript and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable
Additional information about this Adis Drug Review can be found here.
Abstract
Olanzapine/samidorphan (LYBALVI®) is a useful treatment option for patients with schizophrenia or bipolar I disorder who could beneft from the antipsychotic efcacy of olanzapine, but for whom the potential for olanzapine-associated weight gain might otherwise preclude its use. In clinical trials (ENLIGHTEN-1 and ENLIGHTEN-2) in patients with schizophrenia, olanzapine/samidorphan had similar efcacy to olanzapine; samidorphan did not appear to impact the antipsychotic efcacy of olanzapine. In addition, olanzapine/samidorphan led to signifcantly less weight gain than olanzapine in ENLIGHTEN-2. Sustained benefts of olanzapine/samidorphan were evident with longer-term therapy
© Springer Nature Switzerland AG 2022
